(Adds Outlook)
Integra LifeSciences Holdings Corporation (IART) has initiated third-quarter outlook while also cutting its annual guidance, below the Street view.
For the quarter, the company expects adjusted earnings per share of $0.36 to $0.44, below analysts' forecast of $0.85 per share. Revenue is projected to be in the range of $372 million to $382 million, lesser than the Street view of $432.11 million.
For the full year, Integra now anticipates annual adjusted EPS of $2.41 to $2.57, lower than the earlier outlook of $3.01 to $3.11 per share. Revenue outlook for the year has also been cut to $1.609 billion to $1.629 billion from $1.672 billion to $1.687 billion guided earlier.
Analysts, on average, expect the firm to earn $3.04 per share on revenue of $1.68 billion, for the year.
The revised annual outlook reflects the temporary shipping holds and significant second half investments in quality system and GMP compliance improvements.
Q2 Results:
Below are the earnings highlights for Integra Lifesciences:
Earnings: -$12.402 million in Q2 vs. $4.184 million in the same period last year. EPS: -$0.16 in Q2 vs. $0.05 in the same period last year. Excluding items, Integra Lifesciences Holdings Corp reported adjusted earnings of $49.007 million or $0.63 per share for the period.
Analysts projected $0.62 per share Revenue: $418.175 million in Q2 vs. $381.267 million in the same period last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.